Trial Profile

A Clinical Study to Evaluate Subcutaneously Delivered Long-Acting MASP-2 Inhibitor OMS1029

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 16 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OMS 1029 (Primary)
Indications Unspecified
Focus Adverse reactions
Sponsors Omeros Corporation

Most Recent Events

09 Aug 2022 According to an Omeros Corporation media release, first dose administered earlier this week.
10 May 2022 According to an Omeros Corporation media release, enrollment is targeted to begin this summer.
01 Mar 2022 According to an Omeros Corporation media release, based on PK/PD data to date, dosing in humans is expected to be once-monthly to once-quarterly by subcutaneous or intravenous administration.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com